AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

STAA · NASDAQ · Medical - Instruments & Supplies

STAAR Surgical

Builds implantable lenses used in refractive surgery for vision correction.

$22.11

After-hours close+0.00 (+0.02%)

At close$22.11(−1.27%)

Something off on this page? Send us feedback.

Profile

STAAR Surgical CompanySTAAHealth Care

Sells EVO and Visian implantable Collamer lenses for refractive surgery, with revenue now centered on ICL products after cataract lenses were phased out. Commercial performance is international and shaped by China distributor inventory, surgeon training, regulatory approvals, and competition from laser vision-correction procedures.

Designs, manufactures, and sells implantable Collamer lenses and delivery systems for ophthalmic surgery, with current revenue concentrated in EVO and Visian ICL products for refractive correction. Cataract IOLs have been phased out as the product focus narrowed around ICLs.

Sells through an international refractive-surgery model that depends on trained surgeons, patient awareness, distributors in key markets, and regulatory approvals for each ICL variant. China, Japan, South Korea, and the United States are central disclosed markets, with China distributor inventory driving a recent reset and rebound.

Competes mainly against laser refractive procedures rather than close-copy lens products. Governance is also in transition after the failed Alcon merger process and the appointment of interim co-CEOs.

Company facts

CEOWarren Foust and Deborah Andrews

ListedFeb 24, 1992

ExchangeNASDAQ

HeadquartersLake Forest, CA

CountryUnited States

Employees1,211

CIK0000718937

ISINUS8523123052

Key statistics

Market cap$1.10B

EPS (ttm)$0.0800

P/E (ttm)276.38

ROE1.1%

P/B3.04

P/S3.24

Dividend yield—

Beta0.38vs XLV −0.07

Year to date −6.3% · Average volume (30d) 1.0M

Analysts

Price target, next 12 months$31.50+42.5%Median of 16 analysts · vs the Aug 28 close

ConsensusHold4 of 16 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $22.11

High$40.00+80.9%

Median$31.50+42.5%

Low$27.00+22.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 17, 2026	UBS	Target		$19	$28
Aug 13, 2026	Jefferies	Reiterate	Hold	$60	$28
Aug 13, 2026	William Blair	Target		$45.03	$33
Aug 13, 2026	UBS	Reiterate	Sell		$19
May 14, 2026	Mizuho Securities	Target			$27

Earnings

EPS

Estimate$0.20

ReportedDue Nov 4, 2026

Revenue

Estimate$79.1M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	$0.22	$0.16	−27.7%	$90.6M	$93.5M	+3.2%	−0.31%
May 13, 2026Q1 FY26	$0.05	$0.38	+600.8%	$78.7M	$93.5M	+18.8%	+8.88%
Mar 3, 2026Q4 FY25	$0.18	−$0.20	−211.1%	$75.0M	$57.8M	−22.9%	+1.59%
Nov 5, 2025Q3 FY25	$0.18	$0.46	+155.6%	$75.5M	$94.7M	+25.4%	+5.47%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$42.6M	$44.3M	$94.7M	$57.8M	$93.5M	$93.5M
Gross profit	$28.0M	$32.8M	$77.9M	$43.7M	$67.5M	$69.7M
Operating income	−$57.4M	−$30.0M	$18.5M	−$10.9M	$17.4M	$10.1M
Net income	−$54.2M	−$16.8M	$8.9M	−$18.3M	$5.2M	$8.1M
Diluted EPS	−$1.10	−$0.34	$0.18	−$0.36	$0.10	$0.16
Gross margin	65.8%	74.0%	82.2%	75.7%	72.2%	74.5%
Operating margin	-134.8%	-67.6%	19.5%	-18.9%	18.6%	10.8%

Fiscal years (4-quarter sums)FY21 $230.5M · FY22 $284.4M · FY23 $322.4M · FY24 $313.9M · FY25 $239.4M

Balance sheet, Jul 3, 2026Cash & short-term investments $181.5M · Total debt $35.9M · Total assets $475.2M · Shareholders' equity $365.4M

Dividends

No dividends on record.

Ownership

Institutions 113.67%Insiders 72.13%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 49.79M · Float —

Float — provider float is below the insider stake.

The provider's float is smaller than the insider stake it should exclude, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Broadwood Partners, L.P. · director, 10 percent owner:	32.25M	64.77%	Form 4	Mar 13, 2026
Neal C. Bradsher	16.15M	32.60%	13D	Mar 13, 2026
Broadwood Capital Inc	16.12M	32.38%	13F	Aug 14, 2026
BlackRock, Inc.	6.73M	13.52%	13F	Aug 7, 2026
Madison Avenue Partners, LP	4.18M	8.39%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Mar 11, 2026	Broadwood Partners, L.P.	director, 10 percent owner:	+54,764	$17.52
Mar 12, 2026	Broadwood Partners, L.P.	director, 10 percent owner:	+299,432	$18.12
Mar 13, 2026	Broadwood Partners, L.P.	director, 10 percent owner:	+316,017	$18.62
Jan 9, 2026	Broadwood Partners, L.P.	10 percent owner	+27,485	$22.05
Jan 6, 2026	Broadwood Partners, L.P.	10 percent owner	+336,946	$21.62